Table 4.
Treatment and disposition characteristics of emergency department patients with acute heart failure syndromes by international region
| Treatment | USA, n = 122 | Western Europe, n = 78 | Eastern Europe, n = 293 | P-value |
|---|---|---|---|---|
| CPAP/BiPAP | 7 (5.7%) | 8 (10.3%) | 5 (1.71%) | 0.006 |
| Intravenous diuretics | ||||
| Furosemide | 94 (77.1%) | 62 (79.5%) | 237 (80.9%) | 0.674 |
| Bumetanide | 0 (0.0%) | 6 (7.7%) | 0 (0.0%) | <0.001 |
| Torasemide | 0 (0.0%) | 1 (1.3%) | 1 (0.3%) | 0.366 |
| Intravenous vasodilators | ||||
| Nitroglycerin | 3 (2.5%) | 19 (24.4%) | 96 (32.8%) | <0.001 |
| Nitroprusside | 1 (0.8%) | 1 (1.3%) | 0 (0.0%) | 0.203 |
| Nesiritide | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1.000 |
| Others | ||||
| Nitroglycerin SL | 26 (21.3%) | 1 (1.3%) | 19 (6.5%) | <0.001 |
| Nitroglycerin Topical | 27 (22.1%) | 6 (7.7%) | 1 (0.3%) | <0.001 |
| Sublingual ACEI | 1 (0.8%) | 1 (1.3%) | 19 (6.5%) | 0.012 |
| Inotropes/Vasopressors | ||||
| Dobutamine | 1 (0.8%) | 1 (1.3%) | 16 (5.5%) | 0.034 |
| Dopamine | 0 (0.0%) | 1 (1.3%) | 16 (5.5%) | 0.011 |
| Disposition | <0.001 | |||
| Home | 7 (5.8%) | 6 (9.0%) | 5 (1.8%) | |
| Unmonitored floor | 17 (14.2%) | 43 (64.2%) | 86 (30.5%) | |
| Monitored floor | 68 (56.7%) | 3 (4.5%) | 10 (3.6) | |
| Intensive care unit | 28 (23.3%) | 15 (22.3%) | 171 (60.6%) | |
| Died | 0 (0%) | 0 (0%) | 10 (3.6%) | |
Data are presented as proportions and percentages.
CPAP, continuous positive airway pressure; BiPAP, bilevel positive airway pressure; SL, sublingual; ACEI, angiotensin converting enzyme inhibitor.